An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing ...

Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves—insights that could help researchers develop more effective treatment strategies.

An MRI-based imaging technique developed at the University of Cambridge predicts the response of ovarian cancer tumors to treatment, and rapidly reveals how well treatment is working, in patient ...

In 2022, among U.S. women, there were 65,950 new cases of endometrial cancer and 19,880 new cases of ovarian cancer. In the same year, similar numbers of women died from these diseases: 12,550 ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer. Researchers discuss the findings.

Ovarian cancer remains one of the most aggressive gynecological malignancies. Traditional, platinum-based chemotherapy is the standard frontline treatment providing initial benefit for the ...

Among patients with platinum-resistant or platinum-refractory epithelial ovarian cancer, treatment with Recentin (cediranib)-containing regimens demonstrated clinical benefits in progression-free ...

The FDA approved Avmapki Fakzynja Co-pack for KRAS-mutated, recurrent, low-grade serous ovarian cancer after prior systemic therapy. The RAMP-201 trial showed a 44% response rate, with response ...